Sofinnova Management VIII’s Sophiris Bio, Inc. SPHS Stock Holding History

Sofinnova Management VIII’s Portfolio SPHS Stock Details SPHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-200,000	Closed	-$566K	–	10
2017 Q1	$566K	Hold	200,000	–	–	0.3%	10
2016 Q4	$560K	Buy	+200,000	New	+$566K	0.32%	9

Other funds holding SPHS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sofinnova Management VIII's SPHS Position: Q2 2017 in Review

Sofinnova Management VIII sold out of Sophiris Bio, Inc. (SPHS) in Q2 2017, closing a stake of 200,000 shares — an estimated $566K sold.

Sofinnova Management VIII first reported a position in SPHS in Q4 2016 and held it in 2 quarters. The position peaked at $566K in Q1 2017. 31 funds tracked by Wall St. Rank hold SPHS as of Q2 2017.

Sofinnova Management VIII reported no remaining Sophiris Bio, Inc. position as of Q2 2017 after selling out during the quarter.
Sofinnova Management VIII sold 200,000 Sophiris Bio, Inc. shares in Q2 2017, an estimated $566K.
Sofinnova Management VIII first reported a position in Sophiris Bio, Inc. in Q4 2016 and held it in 2 quarters.
Sofinnova Management VIII's Sophiris Bio, Inc. position peaked at $566K in Q1 2017.
31 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q2 2017.

Based on Sofinnova Management VIII's 13F filing for Q2 2017, filed 19 Jul 2017.